Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Other Non-Current Assets: 2022-2025

Historic Other Non-Current Assets for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to $100,000.

  • InMed Pharmaceuticals' Other Non-Current Assets changed negligibly% to $100,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $100,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $100,000 for FY2025, which is negligibly% changed negligibly from last year.
  • Per InMed Pharmaceuticals' latest filing, its Other Non-Current Assets stood at $100,000 for FY2025, which was down 0.00% from $100,000 recorded in FY2024.
  • InMed Pharmaceuticals' 5-year Other Non-Current Assets high stood at $176,637 for FY2022, and its period low was $100,000 during FY2024.
  • Over the past 3 years, InMed Pharmaceuticals' median Other Non-Current Assets value was $100,000 (recorded in 2025), while the average stood at $101,636.
  • Data for InMed Pharmaceuticals' Other Non-Current Assets shows a maximum YoY plummeted of 40.61% (in 2023) over the last 5 years.
  • InMed Pharmaceuticals' Other Non-Current Assets (Yearly) stood at $176,637 in 2022, then plummeted by 40.61% to $104,908 in 2023, then dropped by 4.68% to $100,000 in 2024, then remained steady at $100,000 in 2025.